… the risk-benefit ratio of inhaled corticosteroid treatment for … , and safety of inhaled corticosteroid
treatment in patients with … risk-benefit ratio of inhaled corticosteroid treatment for COPD. …

… of inhaled corticosteroids. We aimed to ascertain the risk of pneumonia with long-term
inhaled corticosteroid use among patients with chronic obstructive pulmonary disease (COPD). …

… Meta-analysis of 21 studies that evaluated effects on 24-hour or overnight urinary cortisol …
doses of inhaled corticosteroid. The data were analyzed using multiple regression analysis of …

… Elevated levels of systemic and pulmonary inflammation in patients with stable COPD
have led to the development of inhaled corticosteroid (ICS) therapies for such patients. These …

… However, our results contrast with the results from previous meta-analyses that analyzed
the all-cause mortality risk after inhaled therapy containing ICSs in patients with COPD.75, 76, …

… However, an interaction analysis in this study showed that inhaled corticosteroids were
most beneficial in patients with the “classic” asthma profile (allergy, reversibility, non-smoking, …

… The purpose of the study is to estimate the risk of asthma exacerbation in stable asthmatics
who reduce inhaled corticosteroids (ICS) compared to those who maintain a stable ICS dose. …

… This systematic review and meta-analysis explored the association of the risk of pneumonia
in COPD patients that were undergoing treatment using ICS alone or together with LABAs or …

… The aim of this study was to evaluate the association … Our meta-analysis shows that inhaled
corticosteroid use is associated with a modest but statistically significant increase in the risk …

… the use of inhaled corticosteroids (ICS). We aimed to ascertain the risk of upper respiratory
tract infection (URTI) with long-term inhaled corticosteroid use among patients with asthma. …